CAMP4 Therapeutics seeks up to $283 million valuation in US IPO
(Reuters) – CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting a valuation of up to $283 million in its initial public…